M
Mehmet Altan
Researcher at University of Texas MD Anderson Cancer Center
Publications - 124
Citations - 3168
Mehmet Altan is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 69 publications receiving 1571 citations. Previous affiliations of Mehmet Altan include Yale University.
Papers
More filters
Journal ArticleDOI
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Jacqulyne P. Robichaux,Yasir Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki A. Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach +23 more
TL;DR: These data identify poziotinib as a potent, clinically active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the molecular features of TKIs that may circumvent steric changes induced by these mutations.
Journal ArticleDOI
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone,William N. William,Annikka Weissferdt,Cheuk Hong Leung,Heather Lin,Apar Pataer,Myrna C.B. Godoy,Brett W. Carter,Lorenzo Federico,Alexandre Reuben,Abdul Wadud Khan,Hitoshi Dejima,Hitoshi Dejima,Alejandro Francisco-Cruz,Edwin R. Parra,Luisa M. Solis,Junya Fujimoto,Hai T. Tran,Neda Kalhor,Frank V. Fossella,Frank E. Mott,Anne S. Tsao,George R. Blumenschein,Xiuning Le,Jianjun Zhang,Ferdinandos Skoulidis,Jonathan M. Kurie,Mehmet Altan,Charles Lu,Bonnie S. Glisson,Lauren Averett Byers,Yasir Elamin,Reza J. Mehran,David C. Rice,Garrett L. Walsh,Wayne L. Hofstetter,Jack A. Roth,Mara B. Antonoff,Humam Kadara,Cara Haymaker,Chantale Bernatchez,Nadim J. Ajami,Robert R. Jenq,Padmanee Sharma,James P. Allison,Andrew Futreal,Jennifer A. Wargo,Ignacio I. Wistuba,Stephen G. Swisher,J. Jack Lee,Don L. Gibbons,Ara A. Vaporciyan,John V. Heymach,Boris Sepesi +53 more
TL;DR: The results of the phase 2 randomized NEOSTAR trial (NCT03158129) as mentioned in this paper showed that nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates and immunologic memory, and merits further investigation in operable NSCLC.
Journal ArticleDOI
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Giulia Costanza Leonardi,Justin F. Gainor,Mehmet Altan,Sasha Kravets,Suzanne E. Dahlberg,Lydia Gedmintas,Roxana Azimi,Hira Rizvi,Jonathan W. Riess,Matthew D. Hellmann,Matthew D. Hellmann,Mark M. Awad +11 more
TL;DR: In patients with NSCLC with AID treated with a PD-(L)1 inhibitor, exacerbation of AID occurred in a minority of patients and adverse events were generally manageable and infrequently led to permanent discontinuation of immunotherapy.
Journal ArticleDOI
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Elizabeth Jimenez Aguilar,Biagio Ricciuti,Justin F. Gainor,Kenneth L. Kehl,Sasha Kravets,Suzanne E. Dahlberg,Mizuki Nishino,Lynette M. Sholl,Anika E. Adeni,S. Subegdjo,Sara Khosrowjerdi,Rachel Peterson,Subba R. Digumarthy,Corinne Liu,Jennifer L. Sauter,Hira Rizvi,Kathryn C. Arbour,Brett W. Carter,John V. Heymach,Mehmet Altan,Matthew D. Hellmann,Mark M. Awad +21 more
TL;DR: Among patients with NSCLC and PD-L1 expression ≥50% treated with first-line pembrolizumab, clinical outcomes are significantly improved in NSCLCs with an expression level of 90-100% and these findings have implications for treatment selection as well as for clinical trial interpretation and design.
Journal ArticleDOI
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Kurt A. Schalper,Kurt A. Schalper,Daniel E. Carvajal-Hausdorf,Joseph McLaughlin,Mehmet Altan,Vamsidhar Velcheti,Patricia Gaule,Miguel F. Sanmamed,Lieping Chen,Roy S. Herbst,David L. Rimm +10 more
TL;DR: The preferential expression of discrete immune evasion pathways in lung cancer could participate in therapeutic resistance and support design of optimal clinical trials.